An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data
NCT ID: NCT02258854
Last Updated: 2015-10-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
69 participants
INTERVENTIONAL
2014-03-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)
NCT02375685
Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment
NCT01747538
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
NCT02258867
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
NCT01684345
Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)
NCT01965145
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose 2 gevokizumab
Dose 2 gevokizumab
Solution for subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dose 2 gevokizumab
Solution for subcutaneous injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
XOMA (US) LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chandler, Arizona, United States
Phoenix, Arizona, United States
Beverly Hills, California, United States
Redlands, California, United States
Riverside, California, United States
Sacramento, California, United States
Santa Ana, California, United States
Victorville, California, United States
Golden, Colorado, United States
Littleton, Colorado, United States
Bridgeport, Connecticut, United States
Lakeland, Florida, United States
Tampa, Florida, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Ellsworth, Maine, United States
Baltimore, Maryland, United States
Cambridge, Massachusetts, United States
Waltham, Massachusetts, United States
Jackson, Michigan, United States
Royal Oak, Michigan, United States
Omaha, Nebraska, United States
Bloomfield, New Jersey, United States
Teaneck, New Jersey, United States
Belmont, North Carolina, United States
Charlotte, North Carolina, United States
Winston-Salem, North Carolina, United States
Fargo, North Dakota, United States
Dallas, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Salt Lake City, Utah, United States
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
X052132
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.